期刊文献+

黑皮质素类药物治疗肾病综合征研究进展 被引量:7

原文传递
导出
摘要 肾病综合征(nephrotic syndrome,NS)是常见肾脏疾病,治疗药物有限,存在较多患者对现有治疗无反应最终进展至终末期肾脏病。对于新药开发和传统药物新的应用研究一直在进行中。
作者 管娜
出处 《中华儿科杂志》 CAS CSCD 北大核心 2016年第5期398-400,共3页 Chinese Journal of Pediatrics
  • 相关文献

参考文献17

  • 1Goldsmith C J, Hammad S. A review of the re-emergence of adrenocorticotrophic hormone therapy inglomerular disease, more than a drug of last resort? [J]. Clin Kidney J,2015,8(4) :430- 432. DOI : 10. 1093/ekj/sfv046.
  • 2Berg AL, Nilsson-Ehle P, Amadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy [ J ]. Kidney Int, 1999,56 (4) :1534-1543.
  • 3Gong R. Leveraging melanoeortin pathways to treat glomerular diseases[J].Adv Chronic Kidney Dis, 2014, 21 ( 2 ) : 134-151. DOI : 10. 1053/j. aekd. 2013.09. 004.
  • 4鲍浩,龚如军.促肾上腺皮质激素治疗肾性蛋白尿的研究[J].肾脏病与透析肾移植杂志,2011,20(2):154-160. 被引量:3
  • 5Montero-Melendez T. ACTH: The forgotten therapy [ J]. Semin Immunol,2015,27 (3) : 216-226. DOI: 10. 1016/j. smim. 2015. 02. 003.
  • 6Piet CF. Management of nephrosis; the use of long continued hormone therapy [J].Calif Med, 1956,85 ( 3 ) : 152-156.
  • 7Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenoeorticotropic hormone in idiopathic membranousnephropathy [ J ]. Am J Kidney Dis,2006,47 (2) :233-240.
  • 8Bomback AS,Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocortieotropie hormone ( ACTH ) gel [J].Drug Des Devel Ther, 2011, 5:147-153. DOI: 10. 2147/DDDT. S17521.
  • 9Hladunewich MA, Cattran D, Beck LH, et at. A pilot study to determine the dose and effectiveness of adrenocortieotrophic hormone (H. P. Acthar Gel ) in nephrotic syndrome due to idiopathic membranous nephropathy[ J]. Nephrol Dial Transplant, 2014,29(8) :1570-1577. DOI: 10. 1093/ndt/gfu069.
  • 10Lorusso P, Bottai A, Mangione E, et al. Low-dose synthetic adrenocorticotropie hormone-analog therapy for nephrotie patients: results from a single-center pilot study[ Jl. Int J Nephrol Renovase Dis,2015,8:7-12. DOI : 10. 2147/JNRD.S74349.

二级参考文献40

  • 1Gong R,Dworkin LD.ACTH(Acthar Gel) prevents proteinuria and renal injury in the remnant kidney:Evidence for direct podocyte protection.J Am Soc Nephro1,2010,21(548A).
  • 2Berg AL,Nilsson-Ehle P,Amadottir M.Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy.Kidney Int,1999,56(4):1534-1543.
  • 3Ponticelli C,Passerini P,Salvadori M,et al.A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy.Am J Kidney Dis,2006,47(2):233-240.
  • 4Hofstra JM,Brink HS,Van de Kerkhof JJ & W,et al.Treatment with synthetic ACTH in patients with Idiopathic membranous nephropathy and high risk for renal failure.J Am Soc Nephrol,2010,21(680A).
  • 5Picardi L,Villa G,Galli F,et al.ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy.Clin Nephrol,2004,62(5):403-404.
  • 6Bomback As,Tumlin JA,Baranski JJ,et al.The treatment of resistam nephrotic syndrome with Acthar Gel(ACTH).J Am Soc Nephrol,2010,21(93A).
  • 7Tumlin JA.Safety and efficacy of Acthar Gel(ACTH)on albuminuria and progression of diabetic nephropathy in patients with nephrotic range proteinuria.J Am Soe Nephrol,2010,21(678A).
  • 8Berg AL,Nilsson-Ehle P.ACTH lowers serum lipids in steroidtreated hyperlipemic patients with kidney disease.Kidney Int,1996,50(2):538-542.
  • 9Kelly KJ,Wu P,Patterson CE,et al.LOX-1 and inflammation:a new mechanism for renal injury in obesity and diabetes.Am J Physiol Renal Physiol,2008,294(5):F1136-F1145.
  • 10Cheng ZZ,Patari A,Aalto-Setala K,et al.Hypercholesterolemia is a prerequisite for puromycin inducible damage in mouse kidney.Kidney Int,2003,630):107-112.

共引文献23

同被引文献17

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部